semaglutide alzheimer's trial Blockbuster GLP-1 Diabetes and Weight Loss Drugs Fails in Obesity drug semaglutide fails to

Enrolling 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher (without diabetes), SELECT showed that semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a mean follow-up of nearly 40 months

What's more

Genetic variations in appetite receptors, metabolic enzymes, and satiety pathways affect how your body responds to GLP-1 compounds

Its also important to understand that individual responses vary

To conclude, MEDI4166 has been engineered to be a novel long acting GLP-1R agonist peptide with a reduced potency in fusion with an optimized neutralising anti-PCSK9 antibody to deliver glycaemic and weight control in combination with LDL-C lowering